Protein / target

DNA topoisomerase 1

Encoded byTOP1P11387Homo sapiensSwiss-Prot

UniProt: P11387 Ensembl: ENSG00000198900 HGNC: HGNC:11986 NCBI Gene: 7150

Clinically validated

Therapeutic maturity

Approved medicines

Open Targets target-level

View by indication →

Clinical trials

Small-molecule tractable

Druggability

Approved Drug

Protein at a glance

Biological role

Protein serine/threonine kinase

Strongest disease association

Small Cell Lung Carcinoma

Via encoding gene TOP1 · Clinical evidence · score 0.65

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex.

View complete UniProt function annotation

Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone (By similarity). Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Involved in the circadian transcription of the core circadian clock component BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the BMAL1 promoter

Subcellular location

Nucleus, nucleolusNucleus, nucleoplasm

Domains and Gene Ontology detail (39)

Domains & features

Topo IB-type catalytic

Gene Ontology

Cchromosome
Cdense fibrillar component
Cfibrillar center
Cnucleolus
Cnucleoplasm
Cnucleus
CP-body
Cperikaryon
Cprotein-DNA complex
FATP binding
Fchromatin binding
Fchromatin DNA binding

765 aa · 91 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Transcriptional regulationUniProt · GO

View supporting evidence

Transcriptional regulation

·Releases the supercoiling and torsional tension of DNA introduced during the DNA replica…
·RNA polymerase II cis-regulatory region sequence-specific DNA binding
·circadian regulation of gene expression
·rRNA transcription

View underlying pathways (1)

SUMOylation of DNA replication proteins

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

2 medicines · 3 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Breast Neoplasms2 medicines

sacituzumab govitecan trastuzumab deruxtecan

Triple Negative Breast Neoplasms1 medicine

sacituzumab govitecan

Broader indication categories (1)

Neoplasms2 medicines

sacituzumab govitecan trastuzumab deruxtecan

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

10 medicines meet Open Targets' target-level approved-medicine definition; the 2 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

trastuzumab deruxtecan

Narrow target profileApprovedInhibitor

DNA topoisomerase I inhibitor

Indicated for Breast Neoplasms, Neoplasms

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

sacituzumab govitecan

Narrow target profileApprovedInhibitor

DNA topoisomerase I inhibitor

Indicated for Breast Neoplasms, Triple Negative Breast Neoplasms, Neoplasms

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

patritumab deruxtecan

Narrow target profileApprovedInhibitor

DNA topoisomerase I inhibitor

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

datopotamab deruxtecan

Narrow target profileApprovedInhibitor

DNA topoisomerase I inhibitor

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

Becatecarin

Narrow target profilePhase 3Inhibitor

DNA topoisomerase I inhibitor

Direct interaction with this protein · 1 of 3 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TOP1

Gene-level evidence surfaced through the gene TOP1 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Small Cell Lung Carcinoma

0.81Well supported

Clinical evidence dominant · Open Targets 0.65

Neoplasms

0.76Well supported

Clinical evidence dominant · Open Targets 0.60

Carcinoma, Non-Small-Cell Lung

0.74Moderately supported

Clinical evidence dominant · Open Targets 0.58

Uterine Cervical Neoplasms

0.70Moderately supported

Clinical evidence dominant · Open Targets 0.57

Ovarian Neoplasms

0.70Moderately supported

Clinical evidence dominant · Open Targets 0.56

View evidence synthesis (5)

Small Cell Lung CarcinomaWell supported

0.81

agreement 0.69–0.93

Clinical70%Somatic mutation19%Literature11%

Open Targets aggregate 0.65 · 3 independent evidence families

NeoplasmsWell supported

0.76

agreement 0.64–0.88

Clinical77%Literature13%Somatic mutation11%

Open Targets aggregate 0.60 · 3 independent evidence families

Carcinoma, Non-Small-Cell LungModerately supported

0.74

agreement 0.62–0.86

Clinical70%Somatic mutation21%Literature8%

Open Targets aggregate 0.58 · 3 independent evidence families

Uterine Cervical NeoplasmsModerately supported

0.70

agreement 0.55–0.86

Clinical98%Literature2%

Open Targets aggregate 0.57 · 2 independent evidence families

Ovarian NeoplasmsModerately supported

0.70

agreement 0.55–0.86

Clinical91%Literature9%

Open Targets aggregate 0.56 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Small Cell Lung Carcinoma0.65

Neoplasms0.60

Carcinoma, Non-Small-Cell Lung0.58

Uterine Cervical Neoplasms0.57

Ovarian Neoplasms0.56

Triple Negative Breast Neoplasms0.55

Neurodegenerative Diseases0.52

Carcinoma0.51

Drug development

26 compounds recorded · 10 approved · 16 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 5 drugs that target this protein in Forefront's canonical graph (2 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)

DIFLOMOTECANPhase 2

TOPOTECANApproval

LABETUZUMAB GOVITECANPhase 2

CAMPTOTHECIN-20-O-PROPIONATEPhase 2

DATOPOTAMAB DERUXTECANApproval

AR-67Phase 2

MURELETECANPhase 1

BELOTECANApproval

IRINOTECAN HYDROCHLORIDEApproval

SACITUZUMAB GOVITECANApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small molecules — Strong

Approved Drug and Structure with Ligand support this modality.

Protein degraders — Emerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

Other modalities — Strong

Approved Drug support this modality.

View underlying tractability evidence (10)

SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule BinderOC · Approved Drug

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

NeutropeniaClinPGx

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Clinical trials

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

A Phase IV, Open-Label, Single-Arm Study of Prophylaxis for Datopotamab Deruxtecan-related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer (TROPION-SWISH)PHASE4

RECRUITING · via datopotamab deruxtecan · NCT07357597

Pilot Study to Evaluate 64Cu-DOTA-Trastuzumab Imaging in Patients With HER2+ Breast Cancer With Brain Metastatsis Treated With Fam-Trastuzumab DeruxtecanPHASE4

RECRUITING · via trastuzumab deruxtecan · NCT05376878

A Randomized, Open-label, Multicenter, Phase 3 Study of YL202 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of ChemotherapyPHASE3

RECRUITING · via sacituzumab govitecan · NCT07461454

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).PHASE3

RECRUITING · via patritumab deruxtecan · NCT07060807

View all trials (26)

A Global, Interventional, Open-label Trial of T-DXd-based Therapy Followed by Palbociclib, Endocrine Therapy and Dual HER2 Blockade in First-line HER2+/ HR+ Advanced or Metastatic Breast Cancer and Retreatment With T-DXd (DB-Guide)PHASE3

NOT_YET_RECRUITING · via trastuzumab deruxtecan · NCT07683754

A Phase III Randomized Trial of Pembrolizumab in Combination With Sacituzumab Govitecan-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial CancerPHASE3

RECRUITING · via sacituzumab govitecan · NCT06524544

A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)PHASE3

RECRUITING · via datopotamab deruxtecan · NCT07291037

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)PHASE3

RECRUITING · via trastuzumab deruxtecan · NCT06899126

SURVIVE HERoes - A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular RelapsePHASE3

RECRUITING · via trastuzumab deruxtecan · NCT06643585

A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)PHASE3

RECRUITING · via sacituzumab govitecan · NCT06801834

DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial CancerPHASE3

RECRUITING · via trastuzumab deruxtecan · NCT06989112

A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13)PHASE3

RECRUITING · via trastuzumab deruxtecan · NCT06819007

A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)PHASE3

RECRUITING · via trastuzumab deruxtecan · NCT06764875

DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract CancerPHASE3

RECRUITING · via trastuzumab deruxtecan · NCT06467357

A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung CancerPHASE3

RECRUITING · via datopotamab deruxtecan · NCT06350097

A Randomized, Open Label, Multicenter Phase II/III Trial of Sacituzumab Govitecan Compared to Standard of Care in Metastatic, Refractory Colorectal Cancer PatientsPHASE2/PHASE3

RECRUITING · via sacituzumab govitecan · NCT06243393

A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)PHASE3

RECRUITING · via datopotamab deruxtecan · NCT06357533

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)PHASE3

ACTIVE_NOT_RECRUITING · via datopotamab deruxtecan · NCT05555732

A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)PHASE3

ACTIVE_NOT_RECRUITING · via datopotamab deruxtecan · NCT05687266

A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02)PHASE3

ACTIVE_NOT_RECRUITING · via patritumab deruxtecan · NCT05338970

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)PHASE3

ACTIVE_NOT_RECRUITING · via datopotamab deruxtecan · NCT05215340

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)PHASE3

ACTIVE_NOT_RECRUITING · via trastuzumab deruxtecan · NCT05048797

A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 TherapyPHASE3

ACTIVE_NOT_RECRUITING · via sacituzumab govitecan · NCT04579224

An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)PHASE3

ACTIVE_NOT_RECRUITING · via trastuzumab deruxtecan · NCT04739761

A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)PHASE3

ACTIVE_NOT_RECRUITING · via trastuzumab deruxtecan · NCT04704934

Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)PHASE3

ACTIVE_NOT_RECRUITING · via trastuzumab deruxtecan · NCT04784715

Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Primary HER2-negative Breast Cancer Patients With High Relapse Risk After Standard Neoadjuvant Treatment - SASCIAPHASE3

ACTIVE_NOT_RECRUITING · via sacituzumab govitecan · NCT04595565

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)PHASE3

ACTIVE_NOT_RECRUITING · via trastuzumab deruxtecan · NCT04494425

A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsPHASE3

ACTIVE_NOT_RECRUITING · via trastuzumab deruxtecan · NCT03734029

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxanePHASE3

ACTIVE_NOT_RECRUITING · via trastuzumab deruxtecan · NCT03529110

ClinicalTrials.gov via the drug-target graph.

What's happening now

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 4 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

Trial status changed2026-07-21
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Status changed to Completed · ClinicalTrials.gov · via sacituzumab govitecan
Indication expanded2026-06-24
Indication expansion: SACITUZUMAB GOVITECAN (BLA761115)
fda · regulatory · fda · via sacituzumab govitecan
Indication expanded2026-06-24
Indication expansion: SACITUZUMAB GOVITECAN (BLA761115)
fda · regulatory · fda · via sacituzumab govitecan
New publication2026-01-01
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
The New England journal of medicine · 2026 · 3 citations · Europe PMC · via sacituzumab govitecan
New publication2025-05-30
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.
Nature medicine · 2025 · 16 citations · Europe PMC · via patritumab deruxtecan
Regulatory approval2025-04-04
Approval: Datroway (EMA)
ema · regulatory · ema · via datopotamab deruxtecan
Label change2025-03-26
Label change: SACITUZUMAB GOVITECAN (BLA761115)
fda · regulatory · fda · via sacituzumab govitecan
New publication2024-12-01
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2024 · 31 citations · Europe PMC · via trastuzumab deruxtecan
Indication expanded2024-11-22
Indication expansion: SACITUZUMAB GOVITECAN (BLA761115)
fda · regulatory · fda · via sacituzumab govitecan
New publication2024-10-01
Sacituzumab govitecan in HR<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.
Nature medicine · 2024 · 32 citations · Europe PMC · via sacituzumab govitecan
New publication2024-09-13
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
Nature medicine · 2024 · 142 citations · Europe PMC · via trastuzumab deruxtecan
New publication2024-07-31
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 37 citations · Europe PMC · via sacituzumab govitecan

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.